(Q34399317)

1 August 2017

The EGFR as a target for anticancer therapy--focus on cetuximab (English)

1 reference

1 August 2017

1 reference

J Baselga

1

1 reference

1 August 2017

1 September 2001

1 reference

European Journal of Cancer

1 August 2017

1 reference

1 August 2017

37 Suppl 4

1 reference

1 August 2017

S16-22

1 reference

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900233-7

7 January 2021

10.1016/S0959-8049(01)00233-7

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11597400